Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Free Cash Flow: 2015-2025

Historic Free Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$31.3 million.

  • Editas Medicine's Free Cash Flow rose 43.66% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.7 million, marking a year-over-year increase of 5.57%. This contributed to the annual value of -$219.1 million for FY2024, which is 60.05% down from last year.
  • Editas Medicine's Free Cash Flow amounted to -$31.3 million in Q3 2025, which was up 37.71% from -$50.2 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Free Cash Flow peaked at -$23.5 million during Q4 2023, and registered a low of -$60.6 million during Q2 2024.
  • For the 3-year period, Editas Medicine's Free Cash Flow averaged around -$44.1 million, with its median value being -$47.9 million (2025).
  • Per our database at Business Quant, Editas Medicine's Free Cash Flow spiked by 45.11% in 2023 and then crashed by 117.87% in 2024.
  • Over the past 5 years, Editas Medicine's Free Cash Flow (Quarterly) stood at -$37.4 million in 2021, then decreased by 14.62% to -$42.9 million in 2022, then surged by 45.11% to -$23.5 million in 2023, then plummeted by 117.87% to -$51.3 million in 2024, then skyrocketed by 43.66% to -$31.3 million in 2025.
  • Its last three reported values are -$31.3 million in Q3 2025, -$50.2 million for Q2 2025, and -$47.9 million during Q1 2025.